In situ preparation of alendronate-loaded ZIF-8 nanoparticles on electrospun nanofibers for accelerating early osteogenesis in osteoporosis

Bioactive Scaffolds as a Promising Alternative for Enhancing Critical-Size Bone Defect Regeneration in the Craniomaxillofacial Region

“…Alendronate/Zif-8-loaded PCL/Gel scaffolds were implanted into calvarial defects in osteoporotic rats, accelerating cranial bone regeneration more significantly than PCL/Gel scaffolds containing solely Zif-8 or alendronate (Figure II). Authors suggest that Zn ions (Zn 2+ ) released from Zif-8 exerted both osteogenic effects and antibacterial activity whereas alendronate inhibits osteoclast activity contributing to bone regeneration in an osteoporotic animal model …”

“…Authors suggest that Zn ions (Zn 2+ ) released from Zif-8 exerted both osteogenic effects and antibacterial activity whereas alendronate inhibits osteoclast activity contributing to bone regeneration in an osteoporotic animal model. 200 A study where ibuprofen, a nonsteroidal anti-inflammatory drug, and BMP-2 were bound to PCL nanofibrous scaffolds and then grafted into maxillary bone lesions in mice showed increased bone regrowth. Authors suggested that ibuprofen might increase the neovascularization of the newly formed bone, exerting a synergistic osteoinductive effect with BMP-2.…”

“…(II) Alendronate (Aln) and nanoparticles (0.5% Zif-8)-loaded PCL/Gel (PG) scaffolds displayed enhanced osteogenic effects after 4- (upper panels) and 8-weeks (lower panels) postimplantation compared to controls (PG scaffolds loaded only with Aln or Zif-8) in a preclinical model. The figure is reprinted (adapted) with permission from reference under the CC BY-NC-ND license (). (III) Purmorphamine (PUR), a pharmacological agonist of the Hh signaling pathway, packed into sterosomes and bound to PLGA scaffolds via polydopamine (PDA), increased cranial bone regrowth in rats compared to controls (PDA and PDA/sterosome-coated PLGA scaffolds).…”

How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature

“…Recently Al-Baadani et al 91 presented a novel multifunctional MOF-based system for ALN delivery. Electrospun polycaprolactone/gelatin (PG)-blended membrane was embedded with ALN-loaded zeolitic imidazolate framework-8 (ALN/Zif-8) nanoparticles employing solution-phase synthesis.…”

“…Two-step controlled released for 480h – 64% and 15% of the drug was released for Ca-ALN and Mg-ALN correspondingly. [ 90 ] Membrane with MOF Polycaprolactone, gelatin Zif-8 The 0.5 mg/mL ALN concentration was used during synthesis 5 µg/cm 2 of ALN was released during first 4 days, prolonged release for 21 days [ 91 ] Calcium phosphate Octacalcium phosphate Drug content – 5.2 wt% Up to 50 hours [ 96 ] Calcium phosphate cement α-tricalcium phosphate (α-TCP) cements, gelatin Maximum ALN concentration 25 mM Data not presented [ 97 ] Calcium phosphate cement Calcium phosphate cement, stearic acid, Precirol ATO5 (Pre), stearylic alcohol, cutina HR(Cut) and Tristearin Encapsulation efficiency% – higher than 90% Controlled release for at least 21 days [ 98 ] Calcium phosphate cement Calcium phosphate cement, PLGA Drug loaded – 0.5wt% (low ALN dose), 5wt% (high ALN dose) Negligible release up to 14 days; at 15–42 day of experiment the ALN was released at the dose 0.02/0.2mg per day for low and high ALN dose cement; after 148 day, the amount of released drug reached 0,8mg and 12mg for low and high ALN dose cement [ 99 ] Calcium phosphate scaffolds Biphasic calcium phosphate Drug loading – 786.28±6.68 µg in ALN (1 mg)/BCP scaffold; 3638.49±7.12 µg in ALN (5 mg)/BCP scaffold During 28 days, 72.42±1.01%, 19.36±0.16 of ALN was released from ALN (1mg)/BCP scaffold and ALN (5mg)/BCP scaffold respectively [ 100 ] Coating 4-aziobenzoic acid-chitosan Drug loading – 293.84±8.04 µg/plate (73.46±2.01 µg/coating) 15.56µg/day during first week, and 2.6µg/day for 56 days [ 103 ] <...…”